Why the study?
The role of GDMT in patients with cardiogenic shock supported by mechanical circulatory support remains poorly defined, and the feasibility and potential benefits of early GDMT initiation during Impella support were uncertain.
Does early guideline-directed medical therapy exposure at device explantation reduce in-hospital mortality in patients with cardiogenic shock supported by Impella?
Cohort (n=140)
Yes
Does early guideline-directed medical therapy exposure at device explantation reduce in-hospital mortality in patients with cardiogenic shock supported by Impella?
Early initiation of guideline-directed medical therapy during Impella support for cardiogenic shock is feasible in 43% of patients and independently associated with lower in-hospital mortality.
Answers are grounded in this paper and cite their sources.
Supports early GDMT feasibility in Impella-supported shock; leaves open causality and need for randomized confirmation.
BACKGROUND: The role of guideline-directed medical therapy (GDMT) in patients with cardiogenic shock (CS) supported by mechanical circulatory support remains poorly defined. The feasibility and potential benefits of early GDMT initiation during Impella support are uncertain. METHODS: We analyzed a multicenter prospective registry of consecutive patients with CS treated with Impella between 2020 and 2024. GDMT exposure was defined as the number of heart failure therapies administered at device explantation. The primary outcome was in-hospital mortality. Multivariable logistic regression adjusted for clinical severity and early shock trajectory. Landmark analysis excluded patients dying within 5 days, while mixed-effects models accounted for center-level clustering. RESULTS: Among 140 patients (mean age 61 years; 20% female), 40% received concomitant ECMO (ECPella). In-hospital mortality was 38%. At explantation, 43% received at least one GDMT agent. Greater GDMT exposure was independently associated with lower mortality (OR 0.28 per additional therapy; 95% CI 0.14-0.58; p<0.001). This association remained consistent in landmark analysis (adjusted OR 0.31; 95% CI 0.16-0.66; p<0.001) and after excluding patients with cardiac arrest (adjusted OR 0.48; 95% CI 0.23-0.88; p=0.002). A graded relationship between GDMT intensity and survival was observed. Center-level variability was negligible (intraclass correlation coefficient 0.02). CONCLUSIONS: In patients with CS supported by Impella, early GDMT implementation was feasible in a substantial proportion of patients. Greater GDMT exposure at device explantation was associated with lower in-hospital mortality. Ventricular unloading may provide an opportunity to initiate outcome-modifying therapies during the acute phase of CS.
No takes yet. Share an insight, caveat, or question.
Tavazzi et al. (2026) conducted a cohort in Cardiogenic shock supported by Impella (n=140). Guideline-directed medical therapy (GDMT) exposure at Impella explantation vs. Lower or no GDMT exposure at device explantation was evaluated on In-hospital mortality (OR 0.28 per additional therapy, 95% CI 0.14-0.58, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: